Literature DB >> 33923227

Glomerular Diseases in Diabetic Patients: Implications for Diagnosis and Management.

Nestor Oliva-Damaso1, José María Mora-Gutiérrez2, Andrew S Bomback3.   

Abstract

The prevalence of diabetes continues to rise worldwide. In addition to rising rates of diabetic kidney disease, we are also seeing a parallel rise in nondiabetic kidney disease among patients with diabetes. These nondiabetic lesions include focal segmental glomerulosclerosis, IgA nephropathy, membranous nephropathy, and other glomerular diseases. The management of diabetic kidney disease is rapidly evolving to include, beyond glycemic control and renin angiotensin inhibition, the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists. These and other new treatment strategies should be applicable to managing glomerular disease in diabetic patients to reduce toxicities associated with immunosuppression and, in particular, corticosteroids. The prevalence of glomerular disease in diabetic patients is underappreciated. Diagnosis and appropriately treating these diseases remain an important avenue to modify kidney outcomes in diabetic patients.

Entities:  

Keywords:  IgA nephropathy; diabetes mellitus; focal segmental glomerulosclerosis; glomerulonephritis; nondiabetic kidney disease; nondiabetic renal disease; obesity-related glomerulopathy

Year:  2021        PMID: 33923227     DOI: 10.3390/jcm10091855

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  51 in total

1.  Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies.

Authors:  Gianna Mazzucco; Tullio Bertani; Mirella Fortunato; Monica Bernardi; Monica Leutner; Renzo Boldorini; Guido Monga
Journal:  Am J Kidney Dis       Date:  2002-04       Impact factor: 8.860

2.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

3.  Should all patients with diabetes have a kidney biopsy?

Authors:  M Luiza Caramori
Journal:  Nephrol Dial Transplant       Date:  2017-01-01       Impact factor: 5.992

4.  Clinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus.

Authors:  S K Mak; E Gwi; K W Chan; P N Wong; K Y Lo; K F Lee; A K Wong
Journal:  Nephrol Dial Transplant       Date:  1997-12       Impact factor: 5.992

5.  Remission of proteinuria improves prognosis in IgA nephropathy.

Authors:  Heather N Reich; Stéphan Troyanov; James W Scholey; Daniel C Cattran
Journal:  J Am Soc Nephrol       Date:  2007-10-31       Impact factor: 10.121

Review 6.  Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

Authors:  Sankar D Navaneethan; Sagar U Nigwekar; Ashwini R Sehgal; Giovanni F M Strippoli
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

7.  Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Authors:  Thomas Rauen; Frank Eitner; Christina Fitzner; Claudia Sommerer; Martin Zeier; Britta Otte; Ulf Panzer; Harm Peters; Urs Benck; Peter R Mertens; Uwe Kuhlmann; Oliver Witzke; Oliver Gross; Volker Vielhauer; Johannes F E Mann; Ralf-Dieter Hilgers; Jürgen Floege
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245

8.  DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

Authors:  Howard Trachtman; Peter Nelson; Sharon Adler; Kirk N Campbell; Abanti Chaudhuri; Vimal Kumar Derebail; Giovanni Gambaro; Loreto Gesualdo; Debbie S Gipson; Jonathan Hogan; Kenneth Lieberman; Brad Marder; Kevin Edward Meyers; Esmat Mustafa; Jai Radhakrishnan; Tarak Srivastava; Miganush Stepanians; Vladimír Tesar; Olga Zhdanova; Radko Komers
Journal:  J Am Soc Nephrol       Date:  2018-11       Impact factor: 10.121

9.  Avosentan for overt diabetic nephropathy.

Authors:  Johannes F E Mann; Damian Green; Kenneth Jamerson; Luis M Ruilope; Susan J Kuranoff; Thomas Littke; Giancarlo Viberti
Journal:  J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 10.121

10.  Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2020-02-13       Impact factor: 79.321

View more
  1 in total

1.  A Case of Oxalate Nephropathy in a Known Diabetic Patient following Acute Alcoholic Pancreatitis.

Authors:  John Odhiambo; Hanika Patel; Anderson Mutuiri; Fazal Yakub; Ahmed Sokwala
Journal:  Case Rep Nephrol       Date:  2022-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.